Novartis/Incyte draw blank with Jakafi in COVID-19Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against Share XNovartis/Incyte draw blank with Jakafi in COVID-19https://pharmaphorum.com/news/novartis-incyte-draw-blank-with-jakafi-in-covid-19/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
Novartis takes $485m hit after axing eczema drug from pipelineNovartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Share XNovartis takes $485m hit after axing eczema drug from pipelinehttps://pharmaphorum.com/news/novartis-takes-485m-hit-after-axing-eczema-drug-from-pipeline/
FDA approves Incyte’s Pemazyre for rare bile duct cancerThe FDA has approved Incyte’s Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile Share XFDA approves Incyte’s Pemazyre for rare bile duct cancerhttps://pharmaphorum.com/news/fda-approves-incytes-pemazyre-for-rare-bile-duct-cancer/
FDA to quickly review Novartis’ capmatinib in rare lung cancerThe FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share XFDA to quickly review Novartis’ capmatinib in rare lung cancerhttps://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
Incyte gets much-needed boost as eczema cream trial hits targetUS biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream Share XIncyte gets much-needed boost as eczema cream trial hits targethttps://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
Incyte’s JAK inhibitor for GVHD fails phase 3 trialIncyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a Share XIncyte’s JAK inhibitor for GVHD fails phase 3 trialhttps://pharmaphorum.com/news/incytes-jak-inhibitor-for-gvhd-fails-phase-3-trial/
Incyte shares down sharply after phase 3 skin cancer trial failureTrial tested epacadostat pill in combination with Merck & Co’s Keytruda Share XIncyte shares down sharply after phase 3 skin cancer trial failurehttps://pharmaphorum.com/news/incyte-shares-down-sharply-after-phase-3-skin-cancer-trial-failure/